Study Countries
Cross-source consensus on Study Countries from 1 sources and 5 claims.
1 sources · 5 claims
Risks & contraindications
Background
Where it comes from
Other
Highlighted claims
- The trial is being implemented in Armenia, Georgia, and Tanzania. — Non-randomised trial of a hepatitis C same-day test and treat model using antibody test only for people who inject drugs in Armenia, Georgia and Tanzania: a CUTTS HepC study protocol
- Tanzania has a concentrated hepatitis C epidemic among people who inject drugs. — Non-randomised trial of a hepatitis C same-day test and treat model using antibody test only for people who inject drugs in Armenia, Georgia and Tanzania: a CUTTS HepC study protocol
- Armenia has a centralized national hepatitis C programme that provides RNA testing and sofosbuvir/velpatasvir free of charge. — Non-randomised trial of a hepatitis C same-day test and treat model using antibody test only for people who inject drugs in Armenia, Georgia and Tanzania: a CUTTS HepC study protocol
- Tanzania’s RNA testing still costs approximately US$70 out of pocket. — Non-randomised trial of a hepatitis C same-day test and treat model using antibody test only for people who inject drugs in Armenia, Georgia and Tanzania: a CUTTS HepC study protocol
- Georgia’s national elimination programme achieved a 67% reduction in general-population RNA prevalence by 2021. — Non-randomised trial of a hepatitis C same-day test and treat model using antibody test only for people who inject drugs in Armenia, Georgia and Tanzania: a CUTTS HepC study protocol